21 June 2016 in Frontiers in Neurology
JBJobelle Joyce Anne R. Baldonado
Jobelle Joyce Anne R. Baldonado
Background: Myasthenia gravis is an autoimmune neuromuscular disorder characterized by the production of abnormal autoantibodies directed against the receptors present in the neuromuscular junction. It has been the standard practice to offer thymectomy in all generalized myasthenia gravis patients despite the lack of robust evidence. Objectives: The objectives of this study are to describe the clinical profile and differentiate the clinical outcomes of thymectomy versus non-thymectomy, and thymomatous versus nonthymomatous myasthenia gravis patients in the Philippine General Hospital. Methodology: Between 2009 and 2014, a total of 69 post-thymectomy and 16 nonthymectomy patient records were successfully retrieved. The demographic characteristics, surgical approach and histopathologic results were obtained. The clinical outcome after six months or one year follow-up was also determined and grouped according to the following: 1) complete remission, 2) pharmacological remission, 3) no clinical change 4) worsening symptoms and 5) mortality. Results: Majority of patients were females (68.0%) with a mean age of 39.8 years and a mean duration of myasthenic symptoms of 21 months. Using the MGFA classification, 54.1% of patients fell under Class II and 48.2% of them presented with generalized weakness. In this study, 60.8% of post-thymectomy myasthenia gravis patients had either complete remission or pharmacologic remission compared to 12.5% among non-thymectomy patients (p-value <0.001). No significant difference in the clinical outcome was found between thymomatous and non-thymomatous myasthenia gravis after thymectomy (p-value 0.29). Conclusion: This study showed that both thymomatous and non-thymomatous myasthenia gravis patients who underwent thymectomy had a higher incidence of complete stable remission and pharmacologic remission as compared to myasthenia gravis patients who did not undergo thymectomy. Keywords: myasthenia gravis, thymoma, non-thymomatous, thymectomy
1 December 2018 in World Neurosurgery
KRKrystle Anne R. Del Rosario-Blasco
Krystle Anne R. Del Rosario-Blasco
31 August 2020 in Neurodegenerative Disease Management
Background: Mexiletine is a potential drug in amyotrophic lateral sclerosis (ALS) that has been tested in clinical trials. The objective of this study was to determine the efficacy and safety of me...
1 April 2020 in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
AEAlejandro Enriquez-Marulanda
Alejandro Enriquez-Marulanda
MJMaria Cristina Z. San Jose
Maria Cristina Z. San Jose
+3
Background: Intravenous tissue-type plasminogen activator (IVtPA) is a proven treatment for acute ischemic stroke; however, diabetes mellitus (DM) and previous cerebral infarction (PCI) were considered relative contraindications for thrombolysis within the 3–4.5 h period.Objective: The study aimed to determine the safety and efficacy of IVtPA among diabetic patients with PCI presenting with acute ischemic stroke.Methods: Studies which evaluated the outcome of IVtPA in terms of symptomatic intracerebral hemorrhage (sICH), functional outcome in modified Rankin scale, and death among diabetic patients with PCI presenting with acute ischemic stroke within the 3–4.5 h period were systematically searched until July 2019. Screening and eligibility criteria were applied. Risk of bias was evaluated using the Newcastle–Ottawa Scale. Odds ratios (ORs) with 95% confidence interval (CI) were used to compare measures of treatment effect. Mantel–Haenszel method and random-effects model were also employed.Results: Four registry-based studies with a total of 44,572 patients were included for quantitative synthesis. Giving IVtPA among DM+/PCI+ patients did not result in significantly increased rate of sICH (OR, 1.09; 95% CI, 0.88, 1.36) compared to No DM+/PCI+ patients. However, there was significantly higher mortality (OR, 1.81; 95% CI, 1.60, 2.06) in the DM+/PCI+ group. Conversely, among those who survived, the DM+/PCI+ patients were more functionally independent at 3 months (OR, 0.76; 95% CI, 0.61, 0.94).Conclusion: Limited evidence suggests that thrombolysis in DM+/PCI+ patients does not result in significantly higher incidence of sICH and may improve functional independence. However, the significantly higher mortality in this group warrants an assessment of the individualized risk–benefit ratio in the use of IVtPA.
1 December 2021 in Current Problems in Cancer
CPCyril Jonas M. Planilla
+1
1 December 2019 in Journal of Clinical Neuroscience
JRJose Paciano Baltazar T. Reyes
Jose Paciano Baltazar T. Reyes